Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 3/20 | 0.74 |
| ▸ | PLK1 | P53350 | 3/20 | 0.74 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.68 |
| ▸ | TAB1 | Q15750 | 2/20 | 0.68 |
| ▸ | TYR | P14679 | 1/20 | 0.67 |
| ▸ | FLT3 | P36888 | 4/20 | 0.65 |
| ▸ | RET | P07949 | 2/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | CTRC | Q99895 | 1/20 | 0.56 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 1/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.56 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.56 |
| ▸ | RAF1 | P04049 | 1/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14448903 | 1.00 | PLK4 (0.74) | PLK4PLK1MAP3K7TAB1TYR | |
| SCHEMBL5472653 | 1.00 | PLK4 (0.74) | PLK4PLK1MAP3K7TAB1TYR | |
| SCHEMBL14448921 | 0.89 | PLK4 (0.74) | PLK4PLK1MAP3K7TAB1TYR | |
| SCHEMBL5472947 | 0.89 | PLK4 (0.74) | PLK4PLK1MAP3K7TAB1TYR | |
| SCHEMBL5472949 | 0.89 | PLK4 (0.74) | PLK4PLK1MAP3K7TAB1TYR | |
| SCHEMBL29575545 | 0.89 | PLK4 (0.74) | PLK4PLK1MAP3K7TAB1TYR | |
| SCHEMBL30406420 | 0.89 | PLK4 (0.74) | PLK4PLK1MAP3K7TAB1TYR | |
| SCHEMBL6001674 | 0.86 | PLK4 (0.65) | PLK4PLK1MAP3K7TAB1FLT3 | |
| SCHEMBL16442337 | 0.85 | PLK4 (1.00) | PLK4PLK1MAP3K7TAB1FLT3 | |
| SCHEMBL5476218 | 0.85 | PLK4 (1.00) | PLK4PLK1MAP3K7TAB1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | claimed |
| EP-1696906-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | claimed |
| WO-2005058309-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2005-06-30 | — | — | WO | claimed |
| US-8324267-B2 | Indolin-2-one derivatives as anticarcinogenic agents for treating angiogenesis, lymphangiogenesis, filariasis | FORSCHUNGZENTRUM KARLSRUHE GMBH (DE) | 2012-12-04 | — | — | US | disclosed |
| US-8324267-B2 | Indolin-2-one derivatives as anticarcinogenic agents for treating angiogenesis, lymphangiogenesis, filariasis | FORSCHUNGZENTRUM KARLSRUHE GMBH (DE) | 2012-12-04 | — | — | US | disclosed |
| EP-1406615-B1 | KINASE INHIBITORS AND THE USE THEREOF | KARLSRUHER INST TECHNOLOGIE (DE) | 2010-11-03 | — | — | EP | disclosed |
| EP-1406615-B1 | KINASE INHIBITORS AND THE USE THEREOF | KARLSRUHER INST TECHNOLOGIE (DE) | 2010-11-03 | — | — | EP | disclosed |
| EP-1476187-A4 | METHODS OF EXTENDING CORNEAL GRAFT SURVIVAL | ALLERGAN INC (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | disclosed |
| EP-1696906-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058309-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2005-06-30 | — | — | WO | disclosed |
| US-20040248965-A1 | Kinase inhibitors and the use thereof | FORSCHUNGSZENTRUM KARLSRUHE GMBH (DE) | 2004-12-09 | — | — | US | disclosed |
| EP-1476187-A2 | METHODS OF EXTENDING CORNEAL GRAFT SURVIVAL | Allergan, Inc. (US) | 2004-11-17 | — | — | EP | disclosed |
| EP-1406615-A1 | KINASE INHIBITORS AND THE USE THEREOF | Forschungszentrum Karlsruhe GmbH (DE) | 2004-04-14 | — | — | EP | disclosed |
| US-20030180294-A1 | Methods of extending corneal graft survival | ALLERGAN, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003072029-A2 | METHODS OF EXTENDING CORNEAL GRAFT SURVIVAL | ALLERGAN, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003007943-A1 | KINASE INHIBITORS AND THE USE THEREOF | FORSCHUNGSZENTRUM KARLSRUHE GMBH (DE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248965-A1 | Kinase inhibitors and the use thereof | MAP3K20, MAP3K6, MAP3K1 | PLK4 459/4885PLK1 127/4885MAP3K7 7/4885 |
| US-20070167488-A1 | Novel therapeutic use | MAG, PMP22, MYT1 | PLK4 3502/4885PLK1 1202/4885MAP3K7 2815/4885 |
| US-20030180294-A1 | Methods of extending corneal graft survival | VEGFA, FLT4, FLT1 | PLK4 1831/4885PLK1 680/4885MAP3K7 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.